• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Steroid hormones and medications that alter cancer risks.

作者信息

Thomas D B

机构信息

Department of Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.

出版信息

Cancer. 1988 Oct 15;62(8 Suppl):1755-67. doi: 10.1002/1097-0142(19881015)62:1+<1755::aid-cncr2820621312>3.0.co;2-5.

DOI:10.1002/1097-0142(19881015)62:1+<1755::aid-cncr2820621312>3.0.co;2-5
PMID:3048637
Abstract

Alkylating agents have caused acute nonlymphocytic leukemia (ANLL), probably bladder cancer, and possibly other solid tumors. Phenacetin also has enhanced risk of bladder cancer, and probably also carcinoma of the renal pelvis. Topical nitrogen mustard, potassium arsenite, tar ointments, and methoxsalene have been related to development of nonmelanotic skin cancers. Immunosuppression by azathioprine, usually with prednisone, has enhanced risks of non-Hodgkin's lymphomas, hepatobiliary cancers, and various mesenchymal tumors. Liver cancers have been reported in users of androgenic anabolic steroids, and both hepatic cell adenomas and carcinomas have been associated with use of combined oral contraceptives. These contraceptives reduce risks of endometrial and ovarian carcinomas. Estrogens increase risk of endometrial cancer. Exposure to diethylstilbestrol in utero can result in clear cell carcinomas of the vagina and cervix, and possibly testicular carcinomas.

摘要

相似文献

1
Steroid hormones and medications that alter cancer risks.
Cancer. 1988 Oct 15;62(8 Suppl):1755-67. doi: 10.1002/1097-0142(19881015)62:1+<1755::aid-cncr2820621312>3.0.co;2-5.
2
[Tumor-causing drugs used in clinical medicine].
Minerva Med. 1979 Feb 4;70(6):503-6.
3
Risk factors associated with the use of sex hormones.与使用性激素相关的风险因素。
Anticancer Res. 1987 Sep-Oct;7(5B):943-8.
4
Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review.雌激素和孕激素在子宫内膜癌病因及预防中的作用:综述
Am J Obstet Gynecol. 1983 Jul 15;146(6):696-707. doi: 10.1016/0002-9378(83)91014-1.
5
Drug-induced cancer.药物性癌症
J Natl Cancer Inst. 1972 May;48(5):1267-70.
6
Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.接受环磷酰胺治疗的非霍奇金淋巴瘤患者发生急性非淋巴细胞白血病和白血病前期的风险。与接受其他烷化剂治疗的霍奇金病和卵巢癌患者的结果比较。
Ann Intern Med. 1985 Aug;103(2):195-200. doi: 10.7326/0003-4819-103-2-195.
7
Carcinogenicity studies in animals relevant to the use of anabolic agents in animal production.与在动物生产中使用同化剂相关的动物致癌性研究。
Environ Qual Saf Suppl. 1976(5):227-37.
8
Role of exogenous female hormones in altering the risk of benign and malignant neoplasms in humans.外源性女性激素在改变人类良性和恶性肿瘤风险中的作用。
Cancer Res. 1978 Nov;38(11 Pt 2):3991-4000.
9
Diethylstilbestrol and other sex hormones during pregnancy.孕期的己烯雌酚及其他性激素。
Obstet Gynecol. 1981 Nov;58(5 Suppl):35S-40S.
10
Avoidable cancers in the Nordic countries. Exogenous hormones.北欧国家中可避免的癌症。外源性激素。
APMIS Suppl. 1997;76:132-40.

引用本文的文献

1
Establishment and characterization of novel human primary endometrial cancer cell line (ZJB-ENC1) and its genomic characteristic.新型人原发性子宫内膜癌细胞系(ZJB - ENC1)的建立、鉴定及其基因组特征
J Cancer. 2019 Oct 20;10(25):6466-6474. doi: 10.7150/jca.33013. eCollection 2019.
2
Establishment and characterization of a new human cell line (EJ) derived from endometrial carcinoma.源自子宫内膜癌的一种新的人类细胞系(EJ)的建立与鉴定
Hum Cell. 2002 Dec;15(4):200-6. doi: 10.1111/j.1749-0774.2002.tb00116.x.
3
Dose and time-course evaluation of a redox-based estradiol-chemical delivery system for the brain. I. Tissue distribution.
用于脑部的基于氧化还原的雌二醇化学递送系统的剂量和时间进程评估。I. 组织分布。
Pharm Res. 1990 Oct;7(10):1061-7. doi: 10.1023/a:1015999318729.